A Phase 1b/2a Study to Assess the Safety, Tolerability, PK, and Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Patients With Metastatic Colorectal or Gastric Gastroesophageal Junction Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Vactosertib (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedPacto
- 29 Oct 2019 Status changed from not yet recruiting to recruiting.
- 28 Oct 2018 Status changed from planning to not yet recruiting.
- 01 Aug 2018 New trial record